Skip to main content
رجوع
Watch Compare

Aprea Therapeutics, Inc.

جودة البيانات: 83%
APRE
Nasdaq Manufacturing Chemicals
KWD 0.92
▲ KWD 0.18 (24.93%)
القيمة السوقية: 8.25 M
السعر
KWD 0.72
القيمة السوقية
8.25 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Negative free cash flow of -12.91 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-103.58%
أقل من متوسط القطاع (-53.34%)
ROIC-81.10%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio5.20
Interest CoverageN/A

التقييم

PE (TTM)
-0.65
أعلى من متوسط القطاع (-1.47)
P/B Ratio0.76
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.7 -1.5
P/B 0.8 1.6
ROE % -103.6 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -12.60 M
ROE -103.58% ROA -79.67%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -12.91 M
ROIC -81.10% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.20
Interest Coverage N/A Asset Turnover N/A
Working Capital 11.26 M Tangible Book Value 10.91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.65 Forward P/E N/A
P/B Ratio 0.76 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -156.56%
Market Cap 8.25 M Enterprise Value -5.47 M
Per Share
EPS (Diluted TTM) -1.93 Revenue / Share N/A
FCF / Share -1.13 OCF / Share -1.13
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 102.46%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -12.60 M -12.96 M -14.29 M -112.66 M -37.13 M
EPS (Diluted) -1.93 -2.45 -3.95 -68.16 -1.74
Gross Profit — — — — —
Operating Income -13.23 M -14.32 M -15.47 M — —
EBITDA — — — — —
R&D Expenses — — — — 23.90 M
SG&A Expenses — — — — —
D&A 21,715.0 22,318.0 7,052.0 4,403.0 12,829.0
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15.93 M 23.98 M 22.65 M 30.16 M 56.82 M
Total Liabilities — — — 3.20 M 7.32 M
Shareholders' Equity 12.44 M 19.31 M 16.95 M 25.64 M 49.51 M
Total Debt — — — — —
Cash & Equivalents 14.60 M 22.85 M 21.61 M 28.79 M 53.08 M
Current Assets 15.56 M 23.58 M 22.52 M 30.15 M 56.58 M
Current Liabilities 2.76 M 3.36 M 4.39 M 3.20 M 7.32 M